Robin Park, MD

Associations

• Head and Neck-Endocrine Oncology

Dr. Park's research interests are in the development of effective treatment biomarkers and novel therapies with a focus on early-phase drug development.

Clinical Trial 23647
A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Condition: Head & Neck
Intervention: PYX-201 (); Pembrolizumab (Keytruda)
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Park R, Rind F, Kristoff T, Li J, Schell M, Slebos RJC, Thatikonda S, Chaudhary R, Biernacki MI, Meshkovska Y, Kaldas D, Kim HS, Farinhas J, Hernandez-Prera J, Kirtane K, Hall MS, Amelio AL, Rocco JW, Bhateja P, Steuer C, Bonomi M, Saba NF, Chung CH. Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial. Am J Clin Oncol. 2025 Sep. Pubmedid: 40905435.
• Chaudhary R, Moorhead G, Park R, Li J, Schell MJ, Song X, Tan A, Slebos RJC, Biernacki MI, Freeman SS, Thatikonda S, Meshkovska Y, Hernandez-Prera J, Kirtane K, Guevara-Patino JA, Amelio AL, Rocco JW, Danysh BP, Bonomi M, Saba NF, Haradhvala NJ, Getz G, Chung CH. Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clin Cancer Res. 2025 Oct. Pubmedid: 41117857.